Skip to main
NVCR
NVCR logo

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd is positioned for significant revenue growth as a result of a recent study that may enable glioblastoma patients to start treatment 2-3 months earlier than current practices, potentially increasing revenue per patient by approximately 20-30%. Additionally, the company's expanding presence in key markets like Germany is expected to drive accelerating growth in active patients, serving as a strong indicator of future revenue trajectories through 2026. The anticipated contribution from new markets over the next 12-18 months further supports NovoCure's positive outlook, supplementing existing patient growth drivers.

Bears say

NovoCure Ltd faces a challenging financial outlook, as projected revenue growth is expected to lead to a significant decline in EBITDA over the upcoming quarters. Despite the anticipation of revenues ramping up, estimates indicate that the company may only achieve breakeven EBITDA levels by 2027. This extended timeline for reaching financial stability raises concerns about the company's short-term profitability and overall financial health.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.